Want to see PL:BIO full AI Analyst Report?
Top Page
BIOTON S.A.
(BIO)
Select Model
Select Model
Rating:45Neutral
Price Target:
zł4.00
▲(4.17% Upside)
Action:N/A
Date:09/16/25
Ongoing profitability issues and weak valuation are the primary negatives, despite improvement in revenue and cash flows. The stable, conservative balance sheet helps offset risk, but lack of technical or valuation support leaves the stock well below average attractiveness for investors. The most significant factors are unprofitability and poor valuation, with technicals offering no meaningful boost due to insufficient data.
Positive Factors
Low Leverage
A conservative leverage approach provides BIOTON with financial flexibility and reduces risk, supporting long-term sustainability.
Negative Factors
Low Operating Cash Flow
Low operating cash flow relative to net income suggests that BIOTON may struggle to cover its operational expenses, affecting financial health.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
A conservative leverage approach provides BIOTON with financial flexibility and reduces risk, supporting long-term sustainability.
Read all positive factors
BIOTON S.A. (BIO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
zł326.28M
Dividend YieldN/A
Average Volume (3M)33.62K
Price to Earnings (P/E)80.5
Beta (1Y)0.15
Revenue Growth12.77%
EPS GrowthN/A
CountryPL
Employees361
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.05
Shares Outstanding85,864,200
10 Day Avg. Volume22,695
30 Day Avg. Volume33,619
Financial Highlights & Ratios
PEG Ratio-0.80
Price to Book (P/B)0.56
Price to Sales (P/S)1.17
P/FCF Ratio145.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.14
Revenue Forecast (FY)zł266.00M
BIOTON S.A. Business Overview & Revenue Model
Company Description
Bioton S.A. operates as a biotechnology company, engaged in the creation, production, distribution, and commercialization of a diverse array of pharmaceuticals, medicinal preparations, and active pharmaceutical ingredients. Its primary focus is on...
How the Company Makes Money
BIOTON generates revenue through several key streams, primarily from the sale of its insulin products and biosimilars, which are marketed in various countries. The company has established partnerships with international pharmaceutical companies, e...
BIOTON S.A. Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
67
Positive
Cash Flow
58
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 266.02M | 282.52M | 207.76M | 181.64M | 233.16M | 163.03M |
| Gross Profit | 95.21M | 91.80M | 64.84M | 72.85M | 95.75M | 76.32M |
| EBITDA | 48.20M | 44.18M | 32.57M | 31.26M | 58.56M | 45.09M |
| Net Income | 4.05M | 3.39M | -15.66M | 2.27M | 1.42M | 2.88M |
Balance Sheet | ||||||
| Total Assets | 768.53M | 764.56M | 794.14M | 822.22M | 810.33M | 865.19M |
| Cash, Cash Equivalents and Short-Term Investments | 2.61M | 8.28M | 6.96M | 3.88M | 9.34M | 8.86M |
| Total Debt | 58.75M | 57.16M | 56.57M | 68.69M | 76.39M | 110.08M |
| Total Liabilities | 179.75M | 170.59M | 203.59M | 215.87M | 204.27M | 242.45M |
| Stockholders Equity | 588.77M | 593.97M | 590.55M | 606.36M | 606.06M | 604.51M |
Cash Flow | ||||||
| Free Cash Flow | 836.00K | 2.28M | 24.72M | -4.54M | 26.50M | -7.37M |
| Operating Cash Flow | 13.06M | 15.34M | 36.33M | 39.63M | 56.08M | 5.52M |
| Investing Cash Flow | -12.11M | -13.01M | -11.61M | -36.95M | -29.10M | -4.28M |
| Financing Cash Flow | -1.07M | -1.01M | -21.64M | -8.13M | -26.50M | -14.62M |
BIOTON S.A. Technical Analysis
Negative
3.84
Price Trends
3.85
Negative
4.01
Negative
4.03
Negative
Market Momentum
-0.02
Positive
44.67
Neutral
68.09
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PL:BIO, the sentiment is Negative. The current price of 3.84 is above the 20-day moving average (MA) of 3.82, below the 50-day MA of 3.85, and below the 200-day MA of 4.03, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 44.67 is Neutral, neither overbought nor oversold. The STOCH value of 68.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PL:BIO.
BIOTON S.A. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | zł326.28M | 80.51 | -1.76% | ― | 12.77% | ― | |
41 Neutral | zł126.07M | -2.21 | -95.68% | ― | -53.36% | -45.92% | |
40 Underperform | zł495.60M | -134.33 | -1.15% | ― | -1.63% | 26.23% | |
37 Underperform | zł424.95M | -4.70 | -135.46% | ― | -15.04% | 24.48% | |
34 Underperform | zł451.09M | -9.20 | -150.18% | ― | -82.90% | 2.18% |
* Healthcare Sector Average
PL:BIO
BIOTON S.A.
3.80
-0.37
-8.87%
PL:RVU
Ryvu Therapeutics SA
18.38
-9.52
-34.12%
PL:SVE
Biomed-Lublin Wytwornia Surowic i Szczepionek S.A.
3.02
-1.76
-36.81%
PL:CTX
Captor Therapeutics SA
71.00
30.60
75.74%
PL:SLV
Selvita SA
27.00
-4.30
-13.74%
PL:MAB
Mabion SA
7.80
-1.20
-13.33%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.